BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

463 related articles for article (PubMed ID: 12213688)

  • 1. Double-blind, randomized comparison of mirtazapine and paroxetine in elderly depressed patients.
    Schatzberg AF; Kremer C; Rodrigues HE; Murphy GM;
    Am J Geriatr Psychiatry; 2002; 10(5):541-50. PubMed ID: 12213688
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mirtazapine compared with paroxetine in major depression.
    Benkert O; Szegedi A; Kohnen R
    J Clin Psychiatry; 2000 Sep; 61(9):656-63. PubMed ID: 11030486
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized, double-blind, 24-week study comparing the efficacy and tolerability of mirtazapine and paroxetine in depressed patients in primary care.
    Wade A; Crawford GM; Angus M; Wilson R; Hamilton L
    Int Clin Psychopharmacol; 2003 May; 18(3):133-41. PubMed ID: 12702891
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mirtazapine versus venlafaxine in hospitalized severely depressed patients with melancholic features.
    Guelfi JD; Ansseau M; Timmerman L; Kørsgaard S;
    J Clin Psychopharmacol; 2001 Aug; 21(4):425-31. PubMed ID: 11476127
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and tolerability of mirtazapine versus citalopram: a double-blind, randomized study in patients with major depressive disorder. Nordic Antidepressant Study Group.
    Leinonen E; Skarstein J; Behnke K; Agren H; Helsdingen JT
    Int Clin Psychopharmacol; 1999 Nov; 14(6):329-37. PubMed ID: 10565799
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparisons of the efficacy and tolerability of extended-release venlafaxine, mirtazapine, and paroxetine in treatment-resistant depression: a double-blind, randomized pilot study in a Chinese population.
    Fang Y; Yuan C; Xu Y; Chen J; Wu Z; Cao L; Yi Z; Hong W; Wang Y; Jiang K; Gao K; Cui X; Nierenberg AA;
    J Clin Psychopharmacol; 2010 Aug; 30(4):357-64. PubMed ID: 20571433
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mirtazapine versus selective serotonin reuptake inhibitors.
    Thompson C
    J Clin Psychiatry; 1999; 60 Suppl 17():18-22; discussion 46-8. PubMed ID: 10446737
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A meta-analysis of eight randomized, double-blind, controlled clinical trials of mirtazapine for the treatment of patients with major depression and symptoms of anxiety.
    Fawcett J; Barkin RL
    J Clin Psychiatry; 1998 Mar; 59(3):123-7. PubMed ID: 9541155
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of the effects of mirtazapine and fluoxetine in severely depressed patients.
    Versiani M; Moreno R; Ramakers-van Moorsel CJ; Schutte AJ;
    CNS Drugs; 2005; 19(2):137-46. PubMed ID: 15697327
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and tolerability of mirtazapine in treating major depressive disorder with anxiety symptoms: an 8-week open-label randomised paroxetine-controlled trial.
    Kim JE; Yoon SJ; Kim J; Jung JY; Jeong HS; Cho HB; Shin E; Lyoo IK; Kim TS
    Int J Clin Pract; 2011 Mar; 65(3):323-9. PubMed ID: 21314870
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early improvement under mirtazapine and paroxetine predicts later stable response and remission with high sensitivity in patients with major depression.
    Szegedi A; Müller MJ; Anghelescu I; Klawe C; Kohnen R; Benkert O
    J Clin Psychiatry; 2003 Apr; 64(4):413-20. PubMed ID: 12716243
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mirtazapine and paroxetine in major depression: a comparison of monotherapy versus their combination from treatment initiation.
    Blier P; Gobbi G; Turcotte JE; de Montigny C; Boucher N; Hébert C; Debonnel G
    Eur Neuropsychopharmacol; 2009 Jul; 19(7):457-65. PubMed ID: 19345072
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Open-label study of mirtazapine orally disintegrating tablets in depressed patients in the nursing home.
    Roose SP; Nelson JC; Salzman C; Hollander SB; Rodrigues H;
    Curr Med Res Opin; 2003; 19(8):737-46. PubMed ID: 14687445
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mirtazapine: efficacy and tolerability in comparison with fluoxetine in patients with moderate to severe major depressive disorder. Mirtazapine-Fluoxetine Study Group.
    Wheatley DP; van Moffaert M; Timmerman L; Kremer CM
    J Clin Psychiatry; 1998 Jun; 59(6):306-12. PubMed ID: 9671343
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mirtazapine orally disintegrating tablets versus venlafaxine extended release: a double-blind, randomized multicenter trial comparing the onset of antidepressant response in patients with major depressive disorder.
    Benkert O; Szegedi A; Philipp M; Kohnen R; Heinrich C; Heukels A; van der Vegte-Senden M; Baker RA; Simmons JH; Schutte AJ
    J Clin Psychopharmacol; 2006 Feb; 26(1):75-8. PubMed ID: 16415711
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Beneficial effects of antidepressant mirtazapine in functional dyspepsia patients with weight loss.
    Jiang SM; Jia L; Liu J; Shi MM; Xu MZ
    World J Gastroenterol; 2016 Jun; 22(22):5260-6. PubMed ID: 27298569
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dual-dual action? Combining venlafaxine and mirtazapine in the treatment of depression.
    Malhi GS; Ng F; Berk M
    Aust N Z J Psychiatry; 2008 Apr; 42(4):346-9. PubMed ID: 18330778
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness of low doses of paroxetine controlled release in the treatment of major depressive disorder.
    Trivedi MH; Pigotti TA; Perera P; Dillingham KE; Carfagno ML; Pitts CD
    J Clin Psychiatry; 2004 Oct; 65(10):1356-64. PubMed ID: 15491239
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Meta-analysis of randomized, double-blind, placebo-controlled, efficacy and safety studies of mirtazapine versus amitriptyline in major depression.
    Stahl S; Zivkov M; Reimitz PE; Panagides J; Hoff W
    Acta Psychiatr Scand Suppl; 1997; 391():22-30. PubMed ID: 9265948
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mirtazapine orally disintegrating tablet versus sertraline: a prospective onset of action study.
    Behnke K; Søgaard J; Martin S; Bäuml J; Ravindran AV; Agren H; Vester-Blokland ED
    J Clin Psychopharmacol; 2003 Aug; 23(4):358-64. PubMed ID: 12920411
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.